Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases

British Journal of Cancer

Volumn 104, Issue 12, 2011, Pages 1877-1881

  Jubb, A M ^a   Cesario, A ^b,c   Ferguson, M ^a   Congedo, M T ^b   Gatter, K C ^a   Lococo, F ^b   Mule A ^d   Pezzella, F ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CATHOLIC UNIVERSITY   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

angiogenesis; brain; metastases; non small cell lung carcinoma; vascular

Indexed keywords

BEVACIZUMAB; CARBONATE DEHYDRATASE IX; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BRAIN METASTASIS; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG SAFETY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; METASTASIS; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; VASCULAR DISEASE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CARBONIC ANHYDRASES; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; PHENOTYPE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79958148848     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.147     Document Type: Article

References (28)

1. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP (2010) Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16: 269-278
2. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL (1995) Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 177: 275-283
3. Gerstner ER, Frosch MP, Batchelor TT (2010) Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 28: e91-e93
4. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL (2001) Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61: 7992-7998 (Pubitemid 33049392)
5. Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ (2008) Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 26: 183-189
6. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70 (Pubitemid 30046295)
7. Huang J, Soffer SZ, Kim ES, McCrudden KW, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ, Kandel JJ (2004) Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2: 36-42 (Pubitemid 38167106)
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342 (Pubitemid 38702844)
9. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H (2005) Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97: 981-989 (Pubitemid 41430564)
10. Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11: 1172-1183
11. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H (2006) Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24: 217-227 (Pubitemid 46622051)
12. Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD, Koeppen HW, Hillan KJ (2004) Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol 57: 504-512 (Pubitemid 38621796)
13. Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, Leek R, Tan EY, Singh B, Mortensen NJ, Noguera-Troise I, Pezzella F, Gatter KC, Thurston G, Fox SB, Harris AL (2009) Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer 101: 1749-1757
14. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049 (Pubitemid 351656458)
15. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844 (Pubitemid 23132159)
16. Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallbohmer D, Park S, Danenberg KD, Takasaki K, Danenberg PV (2006) Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 12: 29-33 (Pubitemid 43166172)
17. Kuzu I, Bicknell R, Harris AL, Jones M, Gatter KC, Mason DY (1992) Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours. J Clin Pathol 45: 143-148
18. 0Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116: 2610-2621 (Pubitemid 44511625)
19. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676
20. Patel NS, Dobbie MS, Rochester M, Steers G, Poulsom R, Le Monnier K, Cranston DW, Li JL, Harris AL (2006) Up-regulation of endothelial deltalike 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 12: 4836-4844 (Pubitemid 44338568)
21. Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, Menard S, Gatter KC, Harris AL, Fox S, Buyse M, Pilotti S, Pierotti M, Rilke F (1997) Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151: 1417-1423 (Pubitemid 27479772)
22. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21: 1804-1809
23. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28: 2137-2143
24. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550 (Pubitemid 44917502)
25. Sington J, Giatromanolaki A, Campo L, Turley H, Pezzella F, Gatter KC (2007) BNIP3 expression in follicular lymphoma. Histopathology 50: 555-560 (Pubitemid 46495827)
26. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W (2009) Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 27: 5255-5261
27. Turley H, Scott PA, Watts VM, Bicknell R, Harris AL, Gatter KC (1998) Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 186: 313-318 (Pubitemid 28494361)
28. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147 (Pubitemid 38524883)